KRYS Krystal Biotech Inc

Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference

Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference

PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Chardan’s 6th Annual Genetic Medicines Conference in New York from October 3-4.

Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host investor meetings on October 4.

A webcast of the presentation will be available beginning at 9:00am ET on Tuesday, October 4 and will be posted on the Investor section of the Company’s .

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit , and follow @KrystalBiotech on and .

CONTACT:

Investors and Media

Meg Dodge

Krystal Biotech



Source: Krystal Biotech, Inc.



EN
29/09/2022

Underlying

KRYSKrystal Biotech Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Krystal Biotech Inc

 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) approved a label update for VYJUVEK® (beremagene geperpavec-svdt) that expands the VYJUVEK eligible patient population to include dystrophic epidermolysis bullosa (DEB) patients from birth and provides patients full flexibility with respect to VYJUVEK ap...

September 15, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Present at Cantor Global Healthcare Conference 2025

Krystal Biotech to Present at Cantor Global Healthcare Conference 2025 PITTSBURGH, Sept. 02, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Cantor Global Healthcare Conference 2025 on September 4, 2025, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:20 am ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 10:20 am ET on Thursday, September 4, 2025 and will be posted on the Investors sectio...

September 2, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces Update on Development Plans for Oncology Pro...

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 (IL-2) and interleukin-12 (IL-12) in the tumor microenvironment and promote systemic immune-mediated tumor clearance following inhaled or intratum...

August 21, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces Second Quarter 2025 Financial and Operating ...

Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results $96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB patients from birth Strong balance sheet, ending the quarter with $820.8 million in cash and investments PITTSBURGH, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the second quarter ending June 30, 2025 and provided a business update. “With the approval of VYJUVEK in Europe and Japan, we ...

August 4, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Report Second Quarter 2025 Financial Results on Aug...

Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on Monday, August 4, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, August 4, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For tho...

July 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch